By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Salix Pharmaceuticals, Ltd. 

1700 Perimeter Park Drive

Morrisville  North Carolina  27560  U.S.A.
Phone: 919-862-1000 Fax: 919-862-1095



Company News
Hedge Fund Takes Stake In Salix Pharmaceuticals, Ltd. (SLXP); Other Top Investors Push For Sale Of Company 12/19/2014 6:29:21 AM
Salix Pharmaceuticals, Ltd. (SLXP) Provides Updates On Wholesaler Inventory Reductions And The XIFAXAN® 550 For IBS-D Approval Timeline, And Provides Preliminary Guidance For 2015 And 2016 12/16/2014 10:39:04 AM
Salix Pharmaceuticals, Ltd. (SLXP) Vows To Fix Inventory Pile-Up Problem By End Of 2015 12/16/2014 6:58:00 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces Plan To Augment Board Of Directors 11/25/2014 8:43:54 AM
Salix Pharmaceuticals, Ltd. (SLXP) Plummets As Accounting Scandal Sinks Deal With Allergan Inc. (AGN), CFO Resigns 11/6/2014 8:04:00 PM
Pharming Group (PHGUF.PK) Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals, Ltd. (SLXP) 11/4/2014 9:23:43 AM
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce The Launch Of Ruconest® In The U.S. For The Treatment Of Acute Angioedema Attacks In Patients With Hereditary Angioedema (HAE) 11/3/2014 10:33:25 AM
Salix Pharmaceuticals, Ltd. (SLXP) Announces 3Q2014 Financial Results Conference Call And Webcast 10/23/2014 11:56:30 AM
Salix Pharmaceuticals, Ltd. (SLXP)’s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea 10/21/2014 11:09:20 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis 10/8/2014 11:09:50 AM